福建广生堂药业股份有限公司 2024 年度独立董事述职报告（陈明宇） 各位股东及股东代表： 2024 年度，作为福建广生堂药业股份有限公司（以下简称"公司"或"广生 堂"）的独立董事，本人严格按照《中华人民共和国公司法》（以下简称"《公 司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）《上市公司 独立董事管理办法》等有关法律、法规、规范性文件及《公司章程》《独立董事 制度》的规定和要求，本着对全体股东负责的态度，勤勉、忠实地履行独立董事 职责，对公司重大事项发表客观、审慎、公正的事前认可或独立意见，积极维护 公司利益和股东特别是中小股东的合法权益。本人于 2024 年 6 月 24 日换届后离 任，现将本人 2024 年任期内的履职情况汇报如下： 一、独立董事的基本情况 （一）独立董事工作履历、专业背景及兼职情况 陈明宇，1963 年出生，中国香港籍，拥有美国福坦莫大学工商管理硕士学 位，并于 2000 年一次性通过五科中国注册税务师考试获取中国注册税务师执业 资格证书。曾先后担任德勤、安永、毕马威企业咨询公司的税务及商务合伙人负 责多家大型中资企业全球财税及并购服务业务；陈明宇先生现任德与安（北 ...

福建广生堂药业股份有限公司 2024 年度独立董事述职报告（鲁凤民） 各位股东及股东代表： 2024 年度，作为福建广生堂药业股份有限公司（以下简称"公司"或"广生 堂"）的独立董事，本人严格按照《中华人民共和国公司法》（以下简称"《公 司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）《上市公司 独立董事管理办法》等有关法律、法规、规范性文件及《公司章程》《独立董事 制度》的规定和要求，本着对全体股东负责的态度，勤勉、忠实地履行独立董事 职责，积极参加股东大会、董事会及专门委员会会议，以审慎的态度对公司董事 会审议的相关重大事项发表了公正、客观的独立意见，切实维护公司和股东特别 是公众股东的合法权益，勤勉尽责地履行了独立董事应尽的职责和义务。本人于 2024 年 6 月 24 日换届后担任公司第五届独立董事，现将本人 2024 年度的履职 情况汇报如下： 二、独立董事年度履职概况 一、独立董事的基本情况 （一）独立董事工作履历、专业背景及兼职情况 鲁凤民，1963 年出生，中国国籍，中共党员。哈尔滨医科大学医学遗传学博 士，博士研究生学历。曾任职于北京医科大学第三医院副研究员，美国费城儿童 医院研 ...

Financial Performance - The company reported a significant narrowing of net loss by 55.16% year-on-year, despite ongoing pressure on gross margins from hepatitis B products due to procurement policies[4]. - Revenue continued to grow, with an overall increase in gross margin exceeding 4 percentage points[4]. - The net cash flow from operating activities turned positive, indicating improved operational quality[4]. - The company's operating revenue for 2024 was ¥441,457,673.77, representing a 4.43% increase compared to ¥422,714,889.10 in 2023[18]. - The net loss attributable to shareholders decreased by 55.16% to ¥156,304,356.74 in 2024 from ¥348,589,843.18 in 2023[18]. - The net cash flow from operating activities improved significantly to ¥20,707,723.30 in 2024, compared to a negative cash flow of ¥174,595,576.92 in 2023, marking an increase of 111.86%[18]. - The total assets at the end of 2024 were ¥1,438,807,956.07, a decrease of 10.88% from ¥1,614,481,833.09 at the end of 2023[18]. - The company reported a basic earnings per share of -¥0.9814 for 2024, an improvement of 55.16% from -¥2.1887 in 2023[18]. - The weighted average return on equity improved to -35.66% in 2024 from -49.90% in 2023, indicating a 14.24% increase[18]. - The company’s net profit before non-recurring gains and losses remained negative, indicating ongoing challenges in achieving profitability[18]. Research and Development - The company plans to maintain its innovation strategy, which has led to increased financial expenses and asset impairment losses[4]. - In 2024, the approval of 48 innovative drugs and 55 rare disease drugs was achieved, along with 106 pediatric drug products, indicating a significant acceleration in drug approval processes[30]. - The company has developed five major antiviral drugs for hepatitis B, including Adefovir, Lamivudine, Entecavir, Tenofovir, and Prodrug Tenofovir, enhancing its competitive advantage in the market[32]. - The innovative drug "Tai Zhong Ding" was approved in 2023, marking the company's first approved innovative product and showcasing its capability in full-cycle drug development[34]. - The company’s hepatitis treatment drug GST-HG141 completed Phase II clinical trials and was included in the national breakthrough therapy category, reflecting its advanced position in hepatitis drug development[34]. - The company is committed to expanding its product pipeline through both internal development and external acquisitions, focusing on innovative drug research and production[36]. - The company has multiple innovative antiviral drug candidates in various stages of clinical trials, enhancing its portfolio and market competitiveness in the hepatitis treatment sector[60]. - The company has established a strong innovation pipeline with a focus on antiviral and liver health drugs, aiming to fill industry gaps and fulfill social responsibilities[64]. Market and Industry Trends - The pharmaceutical industry is projected to grow at a compound annual growth rate (CAGR) of 6.6% from 2024 to 2028, with global drug spending expected to reach approximately $2.2 trillion by 2028[27]. - In 2023, the overall pharmaceutical market in China reached ¥16,333 billion, with a year-on-year growth of 4.3%[28]. - The market for hepatitis B treatment has significant growth potential, with current diagnosis and treatment rates at only 22% and 15%, respectively, compared to WHO targets[38]. Corporate Governance and Management - The company has established a complete and independent governance structure, ensuring compliance with relevant laws and regulations[131]. - The board of directors consists of 9 members, including 3 independent directors, fulfilling legal requirements[134]. - The company has a performance evaluation and incentive mechanism for senior management, linking compensation directly to company performance[138]. - The company maintains independent financial management, with no guarantees provided for shareholders or related parties[141]. - The company has a dedicated investor relations management system, ensuring effective communication with investors[137]. Environmental Responsibility - The company has invested approximately 920,000 RMB in environmental governance and protection for 2024, which includes costs for soil monitoring, pollution source monitoring, and maintenance of pollution control facilities[189]. - The company has obtained an environmental discharge permit valid from November 22, 2024, to November 21, 2029, following the approval from the environmental protection department[183]. - The company has not experienced any environmental violations or accidents as of December 2024, and has established an effective environmental risk management system[186]. - The company’s wastewater treatment process includes a dual A/O + Fenton reagent treatment method, ensuring compliance with discharge standards[185]. Strategic Partnerships and Collaborations - The company established a strategic partnership with the Round Mountain Fund, enhancing its competitive position in the health industry and promoting the integration of traditional Chinese medicine[72]. - The company is actively collaborating with global research institutions to advance its innovative drug development strategy, aiming for a leading position in the industry[49]. Future Outlook and Strategy - Future development strategies and operational plans are subject to market conditions and uncertainties, and do not constitute profit forecasts[5]. - The company aims to achieve a high-quality, leapfrog development by 2025, focusing on both generic and innovative drugs[113]. - The company will deepen marketing reforms and focus on key product breakthroughs, particularly in liver disease products and new traditional Chinese medicine IPs[114]. - The company intends to enhance capital operations and promote financing and acquisitions to support innovative drug clinical research funding needs[115].

广生堂（300436）公告，2024年营业收入4.41亿元，同比增长4.43%。归属于上市公司股东的净亏损 1.56亿元，去年同期净亏损3.49亿元。公司计划不派发现金红利，不送红股，不以公积金转增股本。 ...

Summary of Conference Call on Guangsheng Pharmaceutical Company Overview - Guangsheng Pharmaceutical is a biopharmaceutical company listed on the Shenzhen Stock Exchange's ChiNext board, focusing on antiviral and liver health drug development since its establishment in 2015 [2][3]. Key Developments - The company has made significant progress in its clinical trials, particularly in the antiviral field, with the approval of its COVID-19 drug, Taizhongding, which has the lightest dosage and best antiviral effect among eight drugs in the market [3][4]. - The company is also advancing its hepatitis B treatment pipeline, specifically the drug 141 Nairu Kewei, which has completed a summary report for its Phase II clinical trial [3][4]. Clinical Trials and Innovations - The company is focusing on a unique treatment plan called the "Dengfeng Plan," which aims for clinical cure in hepatitis B patients. This plan includes a combination of existing nucleoside analogs and new drugs targeting hepatitis B core proteins [7][8]. - The drug 131, a small molecule inhibitor targeting surface antigens, is currently in Phase II trials and has shown promising results in reducing surface antigen levels in patients [9][10]. Regulatory Support - Guangsheng Pharmaceutical has received recognition from the National Medical Products Administration (NMPA) for its innovative drug review and approval pilot program, which is expected to expedite the clinical trial process [5][16][17]. - The company is part of a select group of projects recognized for their innovation and clinical data superiority, indicating strong governmental support for its initiatives [17][18]. Market Position and Future Prospects - The company is positioned as a leader in the hepatitis B treatment market, with its drugs being the first in class globally. The combination of 141 and 131 is expected to enhance treatment efficacy and patient outcomes [20][22]. - There is a strong emphasis on the unmet clinical needs in the hepatitis B market, with the company aiming to address these through its innovative treatment strategies [26][27]. Financial Performance - The company reported an expected revenue of approximately 4.35 to 4.6 billion yuan for the year, with a significant increase in gross margins for its main products [41][42]. - Despite a projected loss of 1.25 to 1.63 billion yuan due to increased marketing and team development costs, the company remains optimistic about its growth trajectory [41][42]. Strategic Collaborations - Guangsheng Pharmaceutical collaborates with leading research companies and contract development and manufacturing organizations (CDMOs) to enhance its research capabilities and clinical trial execution [12][13]. - The company is exploring various financing channels to support its innovative drug development, including potential capital market opportunities [47][52]. Conclusion - Guangsheng Pharmaceutical is on a promising path with its innovative hepatitis B treatments and strong regulatory support. The company aims to leverage its unique drug development strategies to meet significant market needs and enhance patient outcomes in the antiviral space [54][56].

近期，广生堂（300436.SZ）发布定增预案，拟向不超过35名特定对象发行股票不超过4778.01万股，募 集资金总额不超过9.77亿元。 《中国经营报》记者注意到，广生堂自2015年上市以来，累计通过IPO、可转债、定增等方式募资超20 亿元，但创新药研发进展缓慢，且此前多个募投项目因"市场环境变化"或"技术障碍"终止。 从此前的经验看，前两次募资的低效执行已为公司敲响警钟；从现实困境看，流动性危机和高负债率让 其转型之路充满不确定性。此次定增能否扭转局面，仍是未知数。 针对此次定增的具体情况，本报记者日前向广生堂方面致函采访，其证券部相关负责人表示，由于公司 临近年报披露期，且定增项目正处于资料准备的密集时期，因此没有过多时间对采访问题进行回复。 前次募投项目"烂尾" 公开资料显示，广生堂主要从事核苷类抗乙肝病毒药物的研发、生产与销售，主要产品包括阿甘定—阿 德福韦酯、贺甘定—拉米夫定、恩甘定—恩替卡韦等核苷类抗乙肝病毒药物。 广生堂方面表示，通过本次向特定对象发行A股股票，有助于进一步扩充公司的资金来源，加快上述创 新药研发进程，扩充公司新产品管线，为公司创造新的利润增长点，增强公司抵御市场风险的能力 ...

前次定增募资未果后，时隔近两年，广生堂（300436）再度抛出了定增募资计划。 广生堂最新公告显示，公司拟向特定对象发行A股股票拟募集资金总额不超过约9.77亿元（含本数），扣除发行费用后全部用于创新药 研发项目、中药传统名方产业化项目以及补充流动资金，拟分别投入募资额5.98亿元、8849.05万元、2.9亿元。 其中，创新药研发项目包括创新药GST-HG141的III期临床研究及上市注册项目、GST-HG131联合GST-HG141的II期及III期临床研究及上 市注册项目。 此外，公司通过收购中药传统名方并建设配套生产线，通过优质工艺、高品质道地药材提升产品品质，以实现更高的附加值，适应国内 快速增长的大健康消费升级需求。 拟定增募资背后，广生堂近年来业绩持续亏损，于2021—2023年连亏三年。财务数据显示，2021—2023年，广生堂实现的营业收入分别 约为3.7亿元、3.86亿元、4.23亿元，对应实现的归属净利润分别为-0.35亿元、-1.27亿元、-3.49亿元。 2024年，广生堂预计继续亏损。公司2024年业绩预告显示，预计实现营业收入4.35亿元至4.6亿元，归属净利润为-1.25亿元至 ...

Core Viewpoint - Guangshentang (300436) announced a private placement plan to issue up to 47.78 million shares, raising no more than 977 million yuan, aimed at funding innovative drug research, traditional Chinese medicine industrialization, and supplementing working capital [1] Group 1: Fundraising and Projects - The private placement will help expand the company's funding sources, accelerate innovative drug development, and create new profit growth points [1] - The total investment for the innovative drug research project is 631 million yuan, with 598 million yuan planned to be funded by the raised capital [2] - The traditional Chinese medicine industrialization project has a total investment of 105 million yuan, with 88.49 million yuan to be funded by the raised capital [2] Group 2: Previous Fundraising Efforts - This is the third private placement since 2020, with previous attempts yielding unsatisfactory results [2][3] - The 2020 private placement raised 514 million yuan, but the projects funded did not meet revenue expectations, leading to significant underperformance [3] - The 2023 private placement was withdrawn due to regulatory changes and strategic considerations [3] Group 3: Financial Performance and Challenges - Guangshentang has faced continuous losses for four years, with a significant decline in revenue from its main products due to price drops from centralized procurement policies [4] - Research and development expenses have increased significantly, accounting for 18.62% to 48.08% of revenue from 2021 to 2023 [5] - The company reported losses of 34.89 million yuan, 127 million yuan, and 349 million yuan from 2021 to 2023, with a projected loss of 125 million to 163 million yuan for 2024 [5] Group 4: Cash Flow and Debt Situation - The company has experienced negative cash flow from operating activities, with net cash flow of -177.65 million yuan in 2021 and -174.36 million yuan in 2024 [6] - The cash reserves have decreased from approximately 200 million yuan at the end of 2023 to 127 million yuan by the end of the third quarter of 2024 [6] - The asset-liability ratio has increased significantly, reaching 67.28% by the end of September 2024 [6]

| 项目名称 | 投资金额 | 拟使用募集资金 | 事集资金是否属 | | --- | --- | --- | --- | | | | 金额 | 于资本化阶段 | | -、创新药研发项目 | 63,100.60 | 59,837.60 | 是 | | 二、中药传统名方产业化 | 10,525.29 | 8,849.05 | 是 | | 三、补充流动资金 | 29,000.00 | 29,000.00 | 否 | | 合计: | 102,625.89 | 97,686.65 | | 截至预案公告日，公司尚未确定具体的发行对象，因而无法确定发行对象与公司的关系。 中国经济网北京4月3日讯广生堂（300436）(300436.SZ)昨晚披露《2025年度向特定对象发行A股股票预 案》称，本次向特定对象发行A股股票的发行对象为不超过35名(含)的特定投资者，包括符合中国证监 会规定的证券投资基金管理公司、证券公司、信托公司、财务公司、保险机构投资者、合格境外机构投 资者、人民币合格境外机构投资者，以及符合中国证监会规定的其他法人、自然人或其他合格的投资者 等。其中，证券投资基金管理公司、证券公司、合格境外机构投资者、 ...

Core Viewpoint - The company plans to issue A-shares to specific investors in 2025, which may dilute immediate returns for existing shareholders, but it has proposed measures to compensate for this dilution and ensure the protection of minority investors' rights [2][6][10]. Financial Impact Analysis - The company estimates a net profit range of -195 million to -157 million yuan for 2024, with a potential 50% increase in losses compared to 2024 [3][4]. - Three scenarios for 2025 net profit projections are analyzed: a 50% increase in losses, maintaining 2024 levels, and a 50% reduction in losses [4][5]. - The projected basic and diluted earnings per share (EPS) under these scenarios range from -0.90 to -1.36 yuan [4][5]. Necessity and Reasonableness of the Issuance - The issuance aligns with relevant policies and the company's strategic development plan, indicating its necessity and feasibility [6][7]. Use of Raised Funds - The raised funds will be allocated to "innovative drug R&D," "industrialization of traditional Chinese medicine," and "supplementing working capital," supporting the company's transition from generic drugs to innovative drugs and health consumption sectors [7][8][9]. Company’s Preparedness for Investment Projects - The company has accumulated significant experience and technical barriers in the liver health and antiviral sectors, with a strong talent pool and ongoing patent applications for its drug candidates [9]. Measures to Mitigate Dilution of Immediate Returns - The company will enhance its competitive advantages and profitability, actively implement fundraising projects, and strengthen fund management to mitigate the dilution of immediate returns for shareholders [10][11][12]. Commitments from Key Stakeholders - The company's board and senior management have committed to fulfilling the proposed compensation measures for shareholders, ensuring no unfair benefit is provided to other entities [14][15].